2020-06-300001704292--12-312020Q2false00017042922020-01-012020-06-300001704292zlab:HanhuiPharmaceuticalsIncorporationMemberzlab:ExclusivePromotionAgreementMember2020-06-300001704292country:CN2019-01-012019-12-310001704292srt:MinimumMember2019-01-012019-06-300001704292srt:MaximumMember2019-01-012019-06-300001704292zlab:DeferredRevenueNonCurrentMember2020-01-012020-06-300001704292us-gaap:OtherIncomeMember2020-01-012020-06-300001704292zlab:DeferredRevenueNonCurrentMember2019-01-012019-12-310001704292us-gaap:OtherIncomeMember2019-01-012019-06-300001704292zlab:ZaiLabShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:TurningPointTherapeuticsIncMemberus-gaap:SubsequentEventMember2020-07-012020-07-310001704292zlab:HanhuiPharmaceuticalsIncorporationMemberzlab:ExclusivePromotionAgreementMember2020-04-012020-04-300001704292zlab:HanhuiPharmaceuticalsIncorporationMemberzlab:ExclusivePromotionAgreementMember2020-03-012020-03-310001704292zlab:RegeneronPharmaceuticalsIncorporationMember2020-04-012020-04-300001704292zlab:IncyteMember2019-07-012019-07-310001704292zlab:MacroGenicsIncMember2018-11-012018-11-300001704292zlab:CrescendoBiologicsLtdMember2018-05-012018-05-310001704292zlab:EntasisTherapeuticsHoldingsIncorporationMember2018-04-012018-04-300001704292zlab:FivePrimeTherapeuticsIncorporationMember2017-12-012017-12-310001704292zlab:ParatekBermudaLimitedMember2017-04-012017-04-300001704292zlab:TesaroMember2016-09-012016-09-300001704292zlab:TurningPointTherapeuticsIncMembersrt:MaximumMemberus-gaap:SubsequentEventMember2020-07-012020-07-310001704292zlab:RegeneronPharmaceuticalsIncorporationMembersrt:MaximumMember2020-04-012020-04-300001704292zlab:IncyteMembersrt:MaximumMember2019-07-012019-07-310001704292zlab:DecipheraMembersrt:MaximumMember2019-06-012019-06-300001704292zlab:MacroGenicsIncMembersrt:MaximumMember2018-11-012018-11-300001704292zlab:NovocureLimitedMembersrt:MaximumMember2018-09-012018-09-300001704292zlab:CrescendoBiologicsLtdMembersrt:MaximumMember2018-05-012018-05-310001704292zlab:EntasisTherapeuticsHoldingsIncorporationMembersrt:MaximumMember2018-04-012018-04-300001704292zlab:FivePrimeTherapeuticsIncorporationMembersrt:MaximumMember2017-12-012017-12-310001704292zlab:ParatekBermudaLimitedMembersrt:MaximumMember2017-04-012017-04-300001704292zlab:TesaroMembersrt:MaximumMember2016-09-012016-09-300001704292zlab:DecipheraMember2019-06-012019-06-300001704292zlab:NovocureLimitedMember2018-09-012018-09-300001704292zlab:ZaiLabUSLLCMember2020-01-012020-06-300001704292zlab:ZaiLabSuzhouCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabInternationalTradingShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabHongKongLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabAUSTPtyLtdMember2020-01-012020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2020-01-012020-06-300001704292us-gaap:CommonStockMember2020-01-012020-06-300001704292us-gaap:CommonStockMember2019-01-012019-06-300001704292us-gaap:RetainedEarningsMember2020-06-300001704292us-gaap:AdditionalPaidInCapitalMember2020-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001704292us-gaap:RetainedEarningsMember2019-12-310001704292us-gaap:AdditionalPaidInCapitalMember2019-12-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001704292us-gaap:RetainedEarningsMember2019-06-300001704292us-gaap:AdditionalPaidInCapitalMember2019-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001704292us-gaap:RetainedEarningsMember2018-12-310001704292us-gaap:AdditionalPaidInCapitalMember2018-12-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100017042922019-01-012019-12-3100017042922018-01-012018-12-3100017042922015-03-050001704292zlab:IndependentDirectorsMemberzlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292zlab:IndependentDirectorsMemberzlab:NonVestedRestrictedSharesMember2019-01-012019-12-310001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMember2019-01-012019-12-310001704292zlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-06-300001704292zlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2019-01-012019-12-310001704292zlab:NonVestedRestrictedSharesMember2019-12-310001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-06-300001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-06-300001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-06-300001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-01-012019-12-310001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-01-012019-12-310001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2019-01-012019-12-310001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-06-300001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-06-300001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2019-01-012019-12-310001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2019-01-012019-12-310001704292zlab:CustomerEMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001704292zlab:ZejulaMember2020-01-012020-06-300001704292zlab:OptuneMember2020-01-012020-06-300001704292zlab:CustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300001704292zlab:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300001704292zlab:ZejulaMember2019-01-012019-06-300001704292zlab:OptuneMember2019-01-012019-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMemberzlab:SupplierEMember2020-01-012020-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMemberzlab:SupplierBMember2020-01-012020-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMemberzlab:SupplierCMember2019-01-012019-06-300001704292zlab:RelatedPartyTransactionResearchAndDevelopmentExpensesMemberus-gaap:LimitedLiabilityCompanyMember2020-01-012020-06-300001704292zlab:RelatedPartyTransactionResearchAndDevelopmentExpensesMemberus-gaap:LimitedLiabilityCompanyMember2019-01-012019-06-300001704292us-gaap:LimitedLiabilityCompanyMember2020-01-012020-06-300001704292us-gaap:PropertyPlantAndEquipmentMember2020-06-300001704292zlab:LaboratoryEquipmentMember2020-01-012020-06-300001704292zlab:ElectronicEquipmentMember2020-01-012020-06-300001704292us-gaap:VehiclesMember2020-01-012020-06-300001704292us-gaap:OfficeEquipmentMember2020-01-012020-06-300001704292us-gaap:ManufacturingFacilityMember2020-01-012020-06-300001704292zlab:ManufacturingEquipmentMember2020-06-300001704292zlab:LaboratoryEquipmentMember2020-06-300001704292zlab:ElectronicEquipmentMember2020-06-300001704292us-gaap:VehiclesMember2020-06-300001704292us-gaap:OfficeEquipmentMember2020-06-300001704292us-gaap:LeaseholdImprovementsMember2020-06-300001704292us-gaap:ConstructionInProgressMember2020-06-300001704292zlab:ManufacturingEquipmentMember2019-12-310001704292zlab:LaboratoryEquipmentMember2019-12-310001704292zlab:ElectronicEquipmentMember2019-12-310001704292us-gaap:VehiclesMember2019-12-310001704292us-gaap:OfficeEquipmentMember2019-12-310001704292us-gaap:LeaseholdImprovementsMember2019-12-310001704292us-gaap:ConstructionInProgressMember2019-12-310001704292us-gaap:LeaseholdImprovementsMember2020-01-012020-06-300001704292zlab:ZaiLabSuzhouCompanyLimitedMember2019-07-012019-12-310001704292zlab:ZaiLabSuzhouCompanyLimitedMember2019-01-012019-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2019-01-012019-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-06-300001704292us-gaap:LatestTaxYearMember2020-01-012020-06-300001704292us-gaap:EarliestTaxYearMember2020-01-012020-06-300001704292us-gaap:RetainedEarningsMember2020-01-012020-06-300001704292us-gaap:RetainedEarningsMember2019-01-012019-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2018-12-120001704292zlab:ZaiLabSuzhouCompanyLimitedMember2018-06-250001704292zlab:ZaiLabSuzhouCompanyLimitedMember2020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2018-12-122018-12-120001704292zlab:ZaiLabSuzhouCompanyLimitedMember2018-06-252018-06-250001704292zlab:ZaiLabHongKongLimitedMember2020-01-012020-06-300001704292zlab:JINGMedicineTechnologyShanghaiLtdMember2020-01-012020-06-300001704292zlab:JINGMedicineTechnologyShanghaiLtdMember2019-01-012019-06-300001704292country:US2020-01-012020-06-300001704292country:KY2020-01-012020-06-300001704292country:HK2020-01-012020-06-300001704292country:AU2020-01-012020-06-300001704292zlab:ZaiLabUSLLCMember2019-01-012019-06-300001704292zlab:ZaiLabAUSTPtyLtdMember2019-01-012019-06-300001704292country:US2019-01-012019-06-300001704292country:KY2019-01-012019-06-300001704292country:HK2019-01-012019-06-300001704292country:AU2019-01-012019-06-300001704292srt:MinimumMember2020-01-012020-06-300001704292srt:MaximumMember2020-01-012020-06-300001704292zlab:JINGMedicineTechnologyShanghaiLtdMember2017-06-300001704292us-gaap:EmployeeStockOptionMember2020-06-300001704292zlab:NonVestedRestrictedSharesMember2020-06-300001704292zlab:ZaiLabHongKongLimitedMemberzlab:ProfitsOfFirstTwoMillionMember2020-01-012020-06-300001704292zlab:ZaiLabHongKongLimitedMemberzlab:ProfitsOfAboveTwoMillionMember2020-01-012020-06-300001704292zlab:ZaiLabUSLLCMember2020-01-012020-06-300001704292zlab:ZaiLabSuzhouCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabInternationalTradingShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabAUSTPtyLtdMember2020-01-012020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2020-01-012020-06-300001704292country:CN2020-01-012020-06-300001704292country:CN2019-01-012019-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMember2020-01-012020-06-300001704292us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2020-01-012020-06-300001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2019-01-012019-12-310001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMember2019-01-012019-06-300001704292us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300001704292us-gaap:CommonStockMember2020-06-300001704292us-gaap:CommonStockMember2019-12-310001704292us-gaap:CommonStockMember2019-06-300001704292us-gaap:CommonStockMember2018-12-3100017042922018-12-310001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2020-06-300001704292currency:USD2020-06-300001704292currency:HKD2020-06-300001704292currency:CNY2020-06-300001704292currency:AUD2020-06-300001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2019-12-310001704292currency:USD2019-12-310001704292currency:HKD2019-12-310001704292currency:CNY2019-12-310001704292currency:AUD2019-12-3100017042922019-06-300001704292zlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMember2019-01-012019-12-310001704292us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001704292country:CN2020-06-300001704292country:CN2019-12-310001704292zlab:NonVestedRestrictedSharesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-300001704292zlab:NonVestedRestrictedSharesMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-06-300001704292zlab:NonVestedRestrictedSharesMember2019-01-012019-06-300001704292us-gaap:EmployeeStockOptionMember2019-01-012019-06-300001704292us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001704292us-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-3000017042922019-01-012019-06-3000017042922020-06-3000017042922019-12-31iso4217:USDxbrli:sharesiso4217:CNYiso4217:USDxbrli:sharesxbrli:purezlab:segmentzlab:Milestonezlab:leasezlab:item

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2020

Commission Filing Number: 001-38205

ZAI LAB LIMITED

(Translation of registrant’s name into English)

4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

​

​

​

​

​

EXHIBIT INDEX

​

Exhibit No.

    

Description

​

​

​

23.1

​

Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP

99.1

​

Consolidated Financial Statements as of June 30, 2020 and for the six months ended June 30, 2019 (unaudited) and 2020

101.INS

​

Inline XBRL Instance Document - this instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document

101.SCH

​

Inline XBRL Taxonomy Extension Schema

101.CAL

​

Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF

​

Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB

​

Inline XBRL Taxonomy Extension Label Linkbase

101.PRE

​

Inline XBRL Taxonomy Extension Presentation Linkbase

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

​

ZAI LAB LIMITED

​

​

​

​

By:

/s/ Billy Cho

​

Name:

Billy Cho

​

Title:

Chief Financial Officer

Date: September 11, 2020

​

​

​

​

​

​

​

​

​

​

​